Medistem Laboratories, Inc. is an emerging Industy Leader in the development of Stem Cell therapies. Recently, Thomas Ichim, its Chief of Scientific Development, was invited to speak before the Regenerative Medicine Organization Conference. The topic of his address, was “Intellectual Property in Biotechnology”.
For example in the area of cardio valvular dysfunction, Medistem has a patent pending application for the non-surgical regeneration of valve structures involving stem cells, and its use in certain patient situations.
Medistem clearly understands that Intellectual Property remains a cornerstone pillar in the Biotech field. The proper positioning of patents, in offensive and defensive postures, can result in attractive revenue streams from licensing royalities, for emerging firms such as Medistem.
Let us hear your thoughts below: